UBS initiates coverage on SAB Biotherapeutics with a Buy rating and $7 PT.

Wednesday, Jan 7, 2026 3:32 pm ET1min read
SABS--

UBS initiates coverage on SAB Biotherapeutics with a Buy rating and $7 PT.

UBS initiates coverage on SAB Biotherapeutics with a Buy rating and $7 PT.

Comments



Add a public comment...
No comments

No comments yet